Ukoniq (Umbralisib)

Ukoniq is a kinase inhibitor used for the treatment of adult patients with: 

• Relapsed or refractory marginal zone lymphoma (MZL) who have previously received at least one anti-CD20-based regimen. 
• Relapsed or refractory follicular lymphoma (FL) who have previously received at least three lines of systemic therapy. 

Recommended Dosage: The recommended dosage is 800 mg taken orally once daily with food until the disease is progressive or unacceptable toxicity occurs. Swallow the tablets whole. Do not chew, crush, break, or cut tablets. The ukoniq dosage is taken persistently each day. In case vomiting occurs, do not take an additional dose of ukoniq; continue with the very next scheduled dose. If a dose of ukoniq is missed, take the missed dose of ukoniq unless it is less than twelve hours until the next scheduled dose.

• Severe, including fatal, infections occurred in patients treated with Umbralisib. Monitor for any new or worsening signs/symptoms of infection. For Grade 3 or 4 infection, withhold Umbralisib until infection has resolved. 
• Provide prophylaxis for Pneumocystis jirovecii pneumonia (PJP) during therapy with umbralisib 200 mg. Withhold this therapy in patients with suspected PJP of any grade and permanently interrupt in patients with confirmed PJP. 
• Monitor for cytomegalovirus (CMV) infection while on treatment with Umbralisib in patients with a history of cytomegalovirus infection. Consider prophylactic antivirals during treatment to prevent cytomegalovirus infection, including CMV reactivation. 
• Severe neutropenia occurred in patients treated with Umbralisib. Monitor neutrophil counts at least every two weeks for the first two months of treatment and at least weekly in patients with neutrophil counts <1 ×10 to power of 9/L (Grade 3-4). Consider supportive care as appropriate. 
• Serious diarrhea or non-infectious colitis occurred in patients treated with umbralisib tablets. For patients with severe diarrhea (Grade 3, i.e., > 6 stools daily over baseline) or stool with mucus or blood, abdominal pain, change in bowel habits, or peritoneal signs, withhold Umbralisib treatment until resolved and provide supportive care with antidiarrheals or enteric acting steroids as required. 
• Serious hepatotoxicity observed in patients treated with Umbralisib pills. Monitor hepatic function during treatment. For ALT/AST higher than 5 to less than 20 times ULN, withhold therapy until return to less than three times ULN, then resume at a reduced dose.
• Serious cutaneous reactions, including fatal cases of exfoliative dermatitis, observed in patients treated with ukoniq 200 mg tablet. Assess patients for new or worsening cutaneous reactions. Review all concomitant drugs and interrupt any potentially contributing medicines. Evaluate at least on a weekly basis until resolved.
• Based on findings and its mechanism of action, Umbralisib can cause fetal harm if administered to a pregnant woman. Females of reproductive age and males with female partners of reproductive age should use appropriate contraception during therapy and for 30 days after the final dose
•  

Urgent Meds is able to source the UKONIQ (Cancer Treatment Medicines) from across the globe and has the ability to supply. Urgent Meds offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Ukoniq®?

Umbralisib is the Generic Name for the trade name drug Ukoniq®.

What is the Manufacturer Name of Ukoniq®?

Ukoniq® is manufactured by TG Therapeutics, Inc.

Is Ukoniq® approved by the FDA?

Yes, Ukoniq® is approved by the FDA. Date of approval: February 5, 2021.

What is Ukoniq®?

Ukoniq is a type of kinase inhibitor, also known as umbralisib tosylate. It is authorized to treat adult patients with Marginal Zone Lymphoma (MZL) or Follicular Lymphoma (FL) that relapsed or did not improve after treatment with other anticancer therapy.

What is the dosage and form of Ukoniq® supplied?

Ukoniq is supplied as Tablets: 200 mg dosage strength for oral administration.

What are the most common side effects due to Ukoniq®?

The most common side effects due to Ukoniq® include rash, fatigue, nausea, neutropenia, transaminase elevation, musculoskeletal pain, anemia, thrombocytopenia, upper respiratory tract infection, vomiting, abdominal pain, and decreased appetite.

How much does Ukoniq® cost in India?

The cost of Ukoniq in India is reasonable. To procure this MZL & FL medicine authentically, you can call or WhatsApp +91-9310090915 or send an email to info@indianpharmanetwork.in.

What are the storage conditions of Ukoniq®?

Store the tablets of Ukoniq at a temperature of 68°F to 77°F (20°C to 25°C). Excursions are permitted between temperatures of 59°F and 86°F (15°C and 30°C).